Epix’ Antidepressant Needs Big Pharma Partner For Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Opportunity seen in companies with antidepressants that are off-patent or don’t have follow-ons.
You may also be interested in...
Epix Pharmaceuticals President Andrew Uprichard: An Interview With “The Pink Sheet” DAILY
Uprichard discusses FDA’s recent encouraging response to Epix’s Vasovist appeal, the regulatory climate for imaging agents, and Epix’s conversion to therapeutics.
Epix Pharmaceuticals President Andrew Uprichard: An Interview With “The Pink Sheet” DAILY
Uprichard discusses FDA’s recent encouraging response to Epix’s Vasovist appeal, the regulatory climate for imaging agents, and Epix’s conversion to therapeutics.
Epix Considers Selling Vasovist If Imaging Agent Clears FDA
FDA agrees to accept a “blinded re-read” of data on the vascular imaging agent as an NDA amendment after Epix appealed “approvable” requests for more studies.